Injectable Peptides Bodybuilding IGF-1 LR3 Polypeptide CAS 946870-92-4

Injectable Peptides Bodybuilding IGF-1 LR3 Polypeptide CAS 946870-92-4

Detail:

Product Name:Igf-1 lr3
Alias:Long R3-IGF-1,IGF-1 Long R3
Molecular formula: C400H625N111O115S9
Molecular Weight : 9117.5
CAS number: 946870-92-4
Appearance : Fine White Lyophilized Powder
Purity : 95%
Specification:0.1mg/vial
Grade : Pharmaceutical Grade

Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).IGF-1 (Insulin-like growth factor) is an endocrine hormone that is produced in the liver. The production of IGF-1 is increased in the presence of growth hormone. There are many different types of cells in the body that are equipped with a receptor to accept IGF-1. This makes IGF-1 a good protagonist at targeting tissues to spur cell to cell communication (growth) or in a more autocrine cell signaling process that facilitates cell division.

IGF-1 LR3 has a half-life of about 20-30 hours and is much more potent than base IGF-1. Since its half-life is about a day, the IGF-1 LR3 will circulate the body, for around 24 hours, binding to receptors and activating cell communication that improves muscle growth and fat loss.

LR3 prevents glucose from entering into cells, which, in turn, forces the body to burn fat and not sucrose. In addition, its long half-life is desirable for another reason; site injections aren't necessary, as IGF-1 LR3 will cycle the body binding to all muscle cells for about a day.

IGF-1 LR3​ Detailed Description

Long(R3)-IGF-l is a synthetic variant of Insulin-Like Growth Factor-1 (IGF-I), a peptide hormone found naturally in the human body. It is a close derivative of this natural protein. The name "Long R3" actually describes how the original IGF-I protein has been modified. It is made by extending the IGF-I protein with a chain of 13 amino acids, and substituting an arginine at the 3rd position.
This new synthetic form of IGF-I seems to retain much of the hormone's original biological activity. It binds and activates the IGF-I receptor with similar affinity, and imparts a similar anabolic effect. However, it also differs by displaying a significantly longer half-life, and higher resistance to binding proteins, in comparison. As a result, milligram for milligram, Long(R3)-IGF-l is estimated to be approximately 2.5 to 3 times more potent than natural IGF-I. In the fitness community, this substance is most commonly used to support increases in muscle mass.

IGF-1 LR3​ Applicattion

IGF-I is an important hormone for human development. Its levels are especially high during childhood and adolescence, where it supports linear growth, as well as the growth of nearly all body tissues. Serum IGF-I levels decline greatly in adulthood, though remain substantial throughout life. This hormone will continue to play important roles in metabolism and physiology, including the support of skeletal muscle mass and strength. IGF-I has several key anabolic/anti-catabolic activities. It supports the synthesis of new muscle protein, satellite cell activity, and the incorporation of new nuclei into muscle cells. It is also noted for reducing the activity of both p27Kip1 and myostatin, which are two powerful inhibitors of muscle growth. As such, IGF-I is regarded as possessing both strong anabolic and anti-catabolic properties.
Long(R3)-IGF-l belongs to the Growth Hormone and Related family of drugs.This is because IGF-I levels increase in response to growth hormone administration. This hormone is actually responsible for most of all of anabolic effect of hGH (somatropin) therapy. Likewise, the two have a very direct relationship in the body. However, it is worth noting that Long(R3)-IGF-l use is likely to be qualitatively different from that of hGH. While its anabolic effects are presumed to be similar, GH imparts a substantial thermogenic effect that is not replicated with Long(R3)-IGF-l.To the contrary, the drug can actually have lipogenic properties similar to insulin. In some users, it increases the tendency for fat gain, not fat loss. Likewise,
Long(R3)-IGF-l would be most closely compared to Increlex (rhIGF-l) therapy instead. Its use is typically characterized by intensified pumps, increased appetite, and moderate increases in lean muscle mass and strength. The stimulation of thermogenesis (fat loss) is not one of this drug's most noteworthy properties.

IGF-1 LR3 influences

Other potential adverse reactions to Long(R3)-IGF-l include joint pain, growth of the tonsils, snoring, headache, dizziness, convulsions, vomiting, ear pain, hearing loss, and hypertrophy of the thymus gland. Long(R3)-IGF-l can stimulate the growth of internal organs. Enlargement of the kidney, spleen, and heart were all noted in studies with recombinant IGF-I therapy. Elevations in cholesterol and triglycerides were also observed.
The overall relationship between Long(R3)-IGF-I use and cardiac changes remains unclear.Thickening of facial soft tissues is also possible, and should be monitored. The abuse of Long(R3)-IGF-l may cause acromegaly, which is characterized by a visible thickening of the bones, most notably the feet, forehead, hands, jaw, and elbows.

Peptide List